Preferred Name |
Nivolumab |
|
Synonyms |
Nivolumab Biosimilar ABP 206 Nivolumab Biosimilar BCD-263 Nivolumab Biosimilar CMAB819 ABP 206 BCD-263 BMS-936558 CMAB819 MDX-1106 NIVO NIVOLUMAB Nivolumab ONO-4538 Opdivo |
|
Definitions |
A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity. |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C68814 |
|
Accepted_Therapeutic_Use_For |
locally advanced or metastatic urothelial carcinoma; recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN); renal cell carcinoma (RCC) ; metastatic melanoma; non-small cell lung cancer (NSCLC); classical Hodgkin lymphoma (cHL); BRAF V600 wild-type, unresectable or metastatic melanoma; metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. |
|
CAS_Registry |
946414-94-4 |
|
code |
C68814 |
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C186328 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C186327 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C186341 |
|
Contributing_Source |
CTRP FDA GDC HemOnc PCDC |
|
DEFINITION |
A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity. |
|
Display_Name |
Nivolumab |
|
FDA_UNII_Code |
31YO63LBSN |
|
FULL_SYN |
Nivolumab Biosimilar ABP 206 Nivolumab Biosimilar BCD-263 Nivolumab Biosimilar CMAB819 ABP 206 BCD-263 BMS-936558 CMAB819 MDX-1106 NIVO NIVOLUMAB Nivolumab ONO-4538 Opdivo |
|
Has_Target | ||
Is_Value_For_GDC_Property | ||
label |
Nivolumab |
|
Legacy Concept Name |
Anti-PD-1_Human_Monoclonal_Antibody_MDX-1106 |
|
Maps_To |
Nivolumab |
|
NCI_Drug_Dictionary_ID |
539733 |
|
PDQ_Closed_Trial_Search_ID |
539733 |
|
PDQ_Open_Trial_Search_ID |
539733 |
|
Preferred_Name |
Nivolumab |
|
prefixIRI |
Thesaurus:C68814 |
|
Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor |
|
UMLS_CUI |
C3657270 |
|
subClassOf |